Ilaris

Active Ingredient(s): Canakinumab
FDA Approved: * June 17, 2009
Pharm Company: * NOVARTIS PHARMS
Category: Anti-Inflammatory

Canakinumab (INN), sold under the brand name Ilaris, is a medication for the treatment of systemic juvenile idiopathic arthritis (SJIA) and active Still's disease, including adult-onset Still's disease (AOSD).[2][3] It is a human monoclonal antibody targeted at interleukin-1 beta. It has no cross-reactivity with other members of the interleukin-1 family, including interleukin-1 alpha.[4] Common side effects include infections (colds and upper re... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.
3 Discussions

Dosage List

Ilaris 150 mg/ml Subcutaneous Injection, Powder, Lyophilized, for Solution

NDC: 0078-0582

Labeler:

Novartis Pharmaceuticals Corporation

Ilaris 150 mg/ml Subcutaneous Injection, Solution

NDC: 0078-0734

Labeler:

Novartis Pharmaceuticals Corporation

Dosage List

Popular Topics